Emily K. Bergsland
Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.
Medical oncologist focused on gastroenteropancreatic neuroendocrine tumours. Chaired the Alliance A021202 trial of pazopanib in progressive carcinoid tumours and co-authors national NET treatment guidelines; leads UCSF's cancer education programmes.
| Title | Journal | Year |
|---|---|---|
| Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors | Journal of the National Comprehensive Cancer Network | 2025 |
| Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors | Hematology/Oncology Clinics of North America | 2016 |
| Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202) | Journal of Clinical Oncology (ASCO Annual Meeting abstract) | 2019 |
Pages like this
not linked directly; found by shared links- InstitutionHolden Comprehensive Cancer Center, University of Iowa
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionUppsala University Hospital / Uppsala University
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- IdeaSSTR antagonist radioligands to increase tumour dose
- PairingSSTR PET → PRRT
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours.
- TrialSANET-ep and SANET-p
Shares VEGF / VEGFR, Neuroendocrine tumours.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonAlan P. Venook
Shares UCSF Helen Diller Family Comprehensive Cancer Center, VEGF / VEGFR.